Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pola Orbis Holdings Inc.

www.po-holdings.co.jp

Latest From Pola Orbis Holdings Inc.

Asia Deal Watch: ReVance Licenses Chinese Rights To Botox Competitor To Fosun

With Phase III data in 2,800 patients for reducing frown lines, ReVance anticipates filing RT002 for US approval in 2019. ABL licenses two bispecific antibody candidates to TRIGR, while Sun looks to expand in dermatology with Pola buyout.

Deals Asia Pacific

In Brief: NPD On Cosmetic Shoppers; African Beauty Market; Avon’s FY 2014

The NPD Group reports a 4% decline in U.S. beauty shoppers in 2014; Avon releases its fiscal 2014 results, while Energizer announces its personal-care spinoff will be called Edgewell Personal Care. More news in brief.

Ranbaxy markets Summit's luliconazole in India

Ranbaxy Laboratories has launched the antifungal luliconazole (marketed as Lulifin) in India. The product is licensed from Japan's Summit Pharmaceuticals International Corporation (SPI).

Japan

Pola deal to boost GSK's Japanese dermal business

Pola Pharma is to begin co-promoting four GlaxoSmithKline topical products in Japan from July 1st, in a tie-up aimed at strengthening the UK group's presence in this sector.

Infectious Diseases Japan
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register